Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

A Single Center, Open-label, Two Cohorts, Fixed Sequence Trial, Investigating the Influence of HRS9531 Injection on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

The purpose of this study is to evaluate the influence of HRS9531 injection on gastric emptying and pharmacokinetics of metformin, atorvastatin, warfarin, and digoxin in healthy subjects.

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes
• Intervention / Treatment: Drug: Metformin; Drug: Digoxin; Drug: Acetaminophen; Drug: Atorvastatin; Drug: Warfarin; Drug: HRS9531

• Study Type: Interventional
• Enrollment (Actual): 57
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Anhui
    • Hefei, Anhui, China, 230000
      • The Second Affiliated Hospital of Anhui Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;
2. Male subjects aged 18-45 years on the date of signing informed consent (inclusive);
3. Body weight ≥60 kg, body mass index (BMI) within the range of 24.0-35.0 kg/m2 (inclusive);
4. HbA1c<6.0%;
5. The subjects have no plans to have children and voluntarily take effective contraceptive measures from the time of signing the informed consent to 2 months after the last medication, and have no plans to donate eggs/sperm; the pregnancy test of female subjects with fertility must be negative.

Exclusion Criteria:

1. Chronic or severe medical history of the respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system, etc., or those with existing systemic diseases mentioned above, and judged by the investigator to be unsuitable to participate in this study;
2. Past history or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2), a history of pancreatitis or symptomatic gallbladder stones;
3. History of disease that increases the risk of bleeding;
4. Surgery within 6 months prior to dosing, planned to undergo surgery during the study period;
5. Participation in clinical trials of any drug or medical device in the 3 months or 5 half-lives, whichever longer, prior to dosing;
6. Blood donation history or blood loss ≥400 mL within 3 months or ≥200 mL within 1 month before dosing, or received blood transfusion within 3 months before dosing;
7. Hepatitis B surface antigen (HBsAg), HIV antibody, hepatitis C virus antibody (HCVAb), treponema pallidum specific antibody detection, positive;
8. Abnormal laboratory test results or abnormal examinations considered unsuitable to participate in this trial;
9. History of hypoglycaemia;
10. History of syncope or vasovagal episodes, difficulty with blood collection, or an inability to tolerate venipuncture;
11. The investigator considers that the subject has any other factors that would make it inappropriate to participate in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment group	Drug: Metformin; Metformin; Drug: Digoxin; Digoxin; Drug: Acetaminophen; Acetaminophen; Drug: Atorvastatin; Atorvastatin; Drug: Warfarin; Warfarin; Drug: HRS9531; HRS9531

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Area under the acetaminophen plasma concentration-time curve	From time 0 to 24 hours after a single dose.
Maximum observed acetaminophen concentration	From time 0 to 24 hours after a single dose.
Time of maximum observed acetaminophen concentration	From time 0 to 24 hours after a single dose.
Area under the metformin plasma concentration-time curve	From time 0 to 12 hours after the last of 7 repeated doses.
Area under the S-warfarin plasma concentration-time curve	From time 0 to 168 hours after a single dose.
Area under the atorvastatin plasma concentration-time curve	From time 0 to 72 hours after a single dose.
Area under the digoxin plasma concentration-time curve	From time 0 to 120 hours after a single dose.

Secondary Outcome Measures

Outcome Measure	Time Frame
Area under the concentration versus time curve of acetaminophen from 0 to infinity	Start of treatment up to 168 hours.
Apparent volume of distribution of acetaminophen	Start of treatment up to 168 hours.
Time of maximum observed metformin concentration after 3.5 days of treatment	Start of Treatment up to 30 hours.
Clearance of metformin after 3.5 days of treatment	Start of Treatment up to 30 hours.
Apparent volume of distribution of metformin after 3.5 days of treatment	Start of Treatment up to 30 hours.
Time of maximum observed S-warfarin concentration	Start of Treatment up to 168 hours.
Clearance of S-warfarin	Start of Treatment up to 168 hours.
Apparent volume of distribution of S-warfarin	Start of Treatment up to 168 hours.
Time of maximum observed atorvastatin (and its active metabolites) concentration	Start of Treatment up to 72 hours.
Clearance of atorvastatin (and its active metabolites)	Start of Treatment up to 72 hours.
Time of maximum observed digoxin concentration	Start of Treatment up to 120 hours.
Maximum observed digoxin concentration	Start of Treatment up to 120 hours.
Clearance of digoxin	Start of Treatment up to 120 hours.
Apparent volume of distribution of digoxin	Start of Treatment up to 120 hours.
Time of maximum observed HRS9532 concentration	Start of Treatment up to 168 hours.
Maximum observed HRS9531 concentration	Start of Treatment up to 168 hours.
Area under the concentration versus time curve of HRS9531 from 0 to the time of the last measurable (positive) concentration	Start of Treatment up to 168 hours.
Area under the concentration versus time curve of HRS9531 from 0 to infinity	Start of Treatment up to 168 hours.
Incidence and severity of adverse events	Screening period up to 117 days.

Collaborators and Investigators

• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): December 18, 2024
• Primary Completion (Actual): June 9, 2025
• Study Completion (Actual): June 9, 2025

Study Registration Dates

• First Submitted: December 5, 2024
• First Submitted That Met QC Criteria: December 5, 2024
• First Posted (Actual): December 9, 2024

Study Record Updates

• Last Update Posted (Actual): June 22, 2025
• Last Update Submitted That Met QC Criteria: June 19, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Hypoglycemic Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Antimetabolites; Sensory System Agents; Analgesics, Non-Narcotic; Analgesics; Antipyretics; Anti-Arrhythmia Agents; Protective Agents; Cardiotonic Agents; Anticoagulants; Anticholesteremic Agents; Hypolipidemic Agents; Lipid Regulating Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Atorvastatin; Acetaminophen; Digoxin; Metformin; Warfarin
• Other Study ID Numbers: HRS9531-107

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No